Page last updated: 2024-09-03

kelatorphan and Allodynia

kelatorphan has been researched along with Allodynia in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Crain, SM; Shen, KF2

Other Studies

2 other study(ies) available for kelatorphan and Allodynia

ArticleYear
Low doses of cyclic AMP-phosphodiesterase inhibitors rapidly evoke opioid receptor-mediated thermal hyperalgesia in naïve mice which is converted to prominent analgesia by cotreatment with ultra-low-dose naltrexone.
    Brain research, 2008, Sep-22, Volume: 1231

    Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Analgesia; Analgesics; Animals; Cyclic AMP; Dipeptides; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Hyperalgesia; Male; Mice; Naltrexone; Narcotic Antagonists; Nociceptors; Phosphodiesterase Inhibitors; Receptors, G-Protein-Coupled; Receptors, Opioid; Receptors, Opioid, kappa; Receptors, Opioid, mu; Signal Transduction; Time Factors

2008
Naloxone rapidly evokes endogenous kappa opioid receptor-mediated hyperalgesia in naïve mice pretreated briefly with GM1 ganglioside or in chronic morphine-dependent mice.
    Brain research, 2007, Sep-05, Volume: 1167

    Topics: Analgesics, Opioid; Animals; Chronic Disease; Dipeptides; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; G(M1) Ganglioside; Hyperalgesia; Male; Mice; Morphine; Morphine Dependence; Naloxone; Naltrexone; Narcotic Antagonists; Nociceptors; Opioid Peptides; Receptors, Opioid, kappa; Substance Withdrawal Syndrome

2007